Company Overview

IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies.

Read More Investor Presentation Corporate Fact Sheet

Latest News

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

July 23, 2026

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

July 21, 2026

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

June 23, 2026

Financial Events

Presentation at the Zacks SCR Life Sciences Virtual Investor Forum

June 25, 2026

Imunon First Quarter 2026 Financial Results

May 12, 2026 at 11:00 AM EDT